Suttorp M et al., Division of Pediatric Hematology-Oncology-Blood and Marrow Transplantation, University Hospital Carl Gustav Carus, Dresden, Germany. 2011 American Society for Blood and Marrow Transplantation.

In this article, the discussion is on the relative merit of the 2 therapeutic approaches and recommend that all children and adolescents with CML-CP should initially be treated with imatinib and maintained with TKI therapy indefinitely if there is a good response.